Report Thumbnail
Product Code LP0912611485XGF
Published Date 2024/3/1
English110 PagesGlobal

Global Breast Cancer Liquid Biopsy Market Growth (Status and Outlook) 2024-2030Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code LP0912611485XGF◆The Mar 2026 edition is also likely available. We will check with the publisher immediately.
Published Date 2024/3/1
English 110 PagesGlobal

Global Breast Cancer Liquid Biopsy Market Growth (Status and Outlook) 2024-2030Pharmaceutical_LifeSciense Market



Abstract


Summary

According to our LPI (LP Information) latest study, the global Breast Cancer Liquid Biopsy market size was valued at US$ 1562.8 million in 2023. With growing demand in downstream market, the Breast Cancer Liquid Biopsy is forecast to a readjusted size of US$ 2226.5 million by 2030 with a CAGR of 5.2% during review period.
The research report highlights the growth potential of the global Breast Cancer Liquid Biopsy market. Breast Cancer Liquid Biopsy are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Breast Cancer Liquid Biopsy. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Breast Cancer Liquid Biopsy market.
Breast Cancer Liquid Biopsy can be usually used in breast biopsy, based on circulating biomarkers, the market is categorized into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers.
Key Features:
The report on Breast Cancer Liquid Biopsy market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Breast Cancer Liquid Biopsy market. It may include historical data, market segmentation by Type (e.g., Circulating Tumor Cells (CTCs), Cell-Free DNA (CfDNA)), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Breast Cancer Liquid Biopsy market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Breast Cancer Liquid Biopsy market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Breast Cancer Liquid Biopsy industry. This include advancements in Breast Cancer Liquid Biopsy technology, Breast Cancer Liquid Biopsy new entrants, Breast Cancer Liquid Biopsy new investment, and other innovations that are shaping the future of Breast Cancer Liquid Biopsy.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Breast Cancer Liquid Biopsy market. It includes factors influencing customer ' purchasing decisions, preferences for Breast Cancer Liquid Biopsy product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Breast Cancer Liquid Biopsy market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Breast Cancer Liquid Biopsy market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Breast Cancer Liquid Biopsy market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Breast Cancer Liquid Biopsy industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Breast Cancer Liquid Biopsy market.
Market Segmentation:
Breast Cancer Liquid Biopsy market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Circulating Tumor Cells (CTCs)
Cell-Free DNA (CfDNA)
Extracellular Vesicles (EVs)
Other Circulating Biomarkers
Segmentation by application
Hospitals
Diagnostic Centers
Laboratories
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
QIAGEN
Roche Diagnostics
Bio-Rad Laboratories
Myriad Genetics
Menarini Silicon Biosystems
Genomic Health
Thermo Fisher Scientific
Illumina
Biocept
Trovagene
Guardant Health
RainDance Technologies
MDx Health

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats
  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global Breast Cancer Liquid Biopsy Market Size 2019-2030
      • 2.1.2 Breast Cancer Liquid Biopsy Market Size CAGR by Region 2019 VS 2023 VS 2030
    • 2.2 Breast Cancer Liquid Biopsy Segment by Type
      • 2.2.1 Circulating Tumor Cells (CTCs)
      • 2.2.2 Cell-Free DNA (CfDNA)
      • 2.2.3 Extracellular Vesicles (EVs)
      • 2.2.4 Other Circulating Biomarkers
    • 2.3 Breast Cancer Liquid Biopsy Market Size by Type
      • 2.3.1 Breast Cancer Liquid Biopsy Market Size CAGR by Type (2019 VS 2023 VS 2030)
      • 2.3.2 Global Breast Cancer Liquid Biopsy Market Size Market Share by Type (2019-2024)
    • 2.4 Breast Cancer Liquid Biopsy Segment by Application
      • 2.4.1 Hospitals
      • 2.4.2 Diagnostic Centers
      • 2.4.3 Laboratories
    • 2.5 Breast Cancer Liquid Biopsy Market Size by Application
      • 2.5.1 Breast Cancer Liquid Biopsy Market Size CAGR by Application (2019 VS 2023 VS 2030)
      • 2.5.2 Global Breast Cancer Liquid Biopsy Market Size Market Share by Application (2019-2024)
  • 3 Breast Cancer Liquid Biopsy Market Size by Player

    • 3.1 Breast Cancer Liquid Biopsy Market Size Market Share by Players
      • 3.1.1 Global Breast Cancer Liquid Biopsy Revenue by Players (2019-2024)
      • 3.1.2 Global Breast Cancer Liquid Biopsy Revenue Market Share by Players (2019-2024)
    • 3.2 Global Breast Cancer Liquid Biopsy Key Players Head office and Products Offered
    • 3.3 Market Concentration Rate Analysis
      • 3.3.1 Competition Landscape Analysis
      • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
    • 3.4 New Products and Potential Entrants
    • 3.5 Mergers & Acquisitions, Expansion
  • 4 Breast Cancer Liquid Biopsy by Regions

    • 4.1 Breast Cancer Liquid Biopsy Market Size by Regions (2019-2024)
    • 4.2 Americas Breast Cancer Liquid Biopsy Market Size Growth (2019-2024)
    • 4.3 APAC Breast Cancer Liquid Biopsy Market Size Growth (2019-2024)
    • 4.4 Europe Breast Cancer Liquid Biopsy Market Size Growth (2019-2024)
    • 4.5 Middle East & Africa Breast Cancer Liquid Biopsy Market Size Growth (2019-2024)
  • 5 Americas

    • 5.1 Americas Breast Cancer Liquid Biopsy Market Size by Country (2019-2024)
    • 5.2 Americas Breast Cancer Liquid Biopsy Market Size by Type (2019-2024)
    • 5.3 Americas Breast Cancer Liquid Biopsy Market Size by Application (2019-2024)
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil
  • 6 APAC

    • 6.1 APAC Breast Cancer Liquid Biopsy Market Size by Region (2019-2024)
    • 6.2 APAC Breast Cancer Liquid Biopsy Market Size by Type (2019-2024)
    • 6.3 APAC Breast Cancer Liquid Biopsy Market Size by Application (2019-2024)
    • 6.4 China
    • 6.5 Japan
    • 6.6 Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia
  • 7 Europe

    • 7.1 Europe Breast Cancer Liquid Biopsy by Country (2019-2024)
    • 7.2 Europe Breast Cancer Liquid Biopsy Market Size by Type (2019-2024)
    • 7.3 Europe Breast Cancer Liquid Biopsy Market Size by Application (2019-2024)
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia
  • 8 Middle East & Africa

    • 8.1 Middle East & Africa Breast Cancer Liquid Biopsy by Region (2019-2024)
    • 8.2 Middle East & Africa Breast Cancer Liquid Biopsy Market Size by Type (2019-2024)
    • 8.3 Middle East & Africa Breast Cancer Liquid Biopsy Market Size by Application (2019-2024)
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends
  • 10 Global Breast Cancer Liquid Biopsy Market Forecast

    • 10.1 Global Breast Cancer Liquid Biopsy Forecast by Regions (2025-2030)
      • 10.1.1 Global Breast Cancer Liquid Biopsy Forecast by Regions (2025-2030)
      • 10.1.2 Americas Breast Cancer Liquid Biopsy Forecast
      • 10.1.3 APAC Breast Cancer Liquid Biopsy Forecast
      • 10.1.4 Europe Breast Cancer Liquid Biopsy Forecast
      • 10.1.5 Middle East & Africa Breast Cancer Liquid Biopsy Forecast
    • 10.2 Americas Breast Cancer Liquid Biopsy Forecast by Country (2025-2030)
      • 10.2.1 United States Breast Cancer Liquid Biopsy Market Forecast
      • 10.2.2 Canada Breast Cancer Liquid Biopsy Market Forecast
      • 10.2.3 Mexico Breast Cancer Liquid Biopsy Market Forecast
      • 10.2.4 Brazil Breast Cancer Liquid Biopsy Market Forecast
    • 10.3 APAC Breast Cancer Liquid Biopsy Forecast by Region (2025-2030)
      • 10.3.1 China Breast Cancer Liquid Biopsy Market Forecast
      • 10.3.2 Japan Breast Cancer Liquid Biopsy Market Forecast
      • 10.3.3 Korea Breast Cancer Liquid Biopsy Market Forecast
      • 10.3.4 Southeast Asia Breast Cancer Liquid Biopsy Market Forecast
      • 10.3.5 India Breast Cancer Liquid Biopsy Market Forecast
      • 10.3.6 Australia Breast Cancer Liquid Biopsy Market Forecast
    • 10.4 Europe Breast Cancer Liquid Biopsy Forecast by Country (2025-2030)
      • 10.4.1 Germany Breast Cancer Liquid Biopsy Market Forecast
      • 10.4.2 France Breast Cancer Liquid Biopsy Market Forecast
      • 10.4.3 UK Breast Cancer Liquid Biopsy Market Forecast
      • 10.4.4 Italy Breast Cancer Liquid Biopsy Market Forecast
      • 10.4.5 Russia Breast Cancer Liquid Biopsy Market Forecast
    • 10.5 Middle East & Africa Breast Cancer Liquid Biopsy Forecast by Region (2025-2030)
      • 10.5.1 Egypt Breast Cancer Liquid Biopsy Market Forecast
      • 10.5.2 South Africa Breast Cancer Liquid Biopsy Market Forecast
      • 10.5.3 Israel Breast Cancer Liquid Biopsy Market Forecast
      • 10.5.4 Turkey Breast Cancer Liquid Biopsy Market Forecast
      • 10.5.5 GCC Countries Breast Cancer Liquid Biopsy Market Forecast
    • 10.6 Global Breast Cancer Liquid Biopsy Forecast by Type (2025-2030)
    • 10.7 Global Breast Cancer Liquid Biopsy Forecast by Application (2025-2030)
  • 11 Key Players Analysis

    • 11.1 QIAGEN
      • 11.1.1 QIAGEN Company Information
      • 11.1.2 QIAGEN Breast Cancer Liquid Biopsy Product Offered
      • 11.1.3 QIAGEN Breast Cancer Liquid Biopsy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.1.4 QIAGEN Main Business Overview
      • 11.1.5 QIAGEN Latest Developments
    • 11.2 Roche Diagnostics
      • 11.2.1 Roche Diagnostics Company Information
      • 11.2.2 Roche Diagnostics Breast Cancer Liquid Biopsy Product Offered
      • 11.2.3 Roche Diagnostics Breast Cancer Liquid Biopsy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.2.4 Roche Diagnostics Main Business Overview
      • 11.2.5 Roche Diagnostics Latest Developments
    • 11.3 Bio-Rad Laboratories
      • 11.3.1 Bio-Rad Laboratories Company Information
      • 11.3.2 Bio-Rad Laboratories Breast Cancer Liquid Biopsy Product Offered
      • 11.3.3 Bio-Rad Laboratories Breast Cancer Liquid Biopsy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.3.4 Bio-Rad Laboratories Main Business Overview
      • 11.3.5 Bio-Rad Laboratories Latest Developments
    • 11.4 Myriad Genetics
      • 11.4.1 Myriad Genetics Company Information
      • 11.4.2 Myriad Genetics Breast Cancer Liquid Biopsy Product Offered
      • 11.4.3 Myriad Genetics Breast Cancer Liquid Biopsy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.4.4 Myriad Genetics Main Business Overview
      • 11.4.5 Myriad Genetics Latest Developments
    • 11.5 Menarini Silicon Biosystems
      • 11.5.1 Menarini Silicon Biosystems Company Information
      • 11.5.2 Menarini Silicon Biosystems Breast Cancer Liquid Biopsy Product Offered
      • 11.5.3 Menarini Silicon Biosystems Breast Cancer Liquid Biopsy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.5.4 Menarini Silicon Biosystems Main Business Overview
      • 11.5.5 Menarini Silicon Biosystems Latest Developments
    • 11.6 Genomic Health
      • 11.6.1 Genomic Health Company Information
      • 11.6.2 Genomic Health Breast Cancer Liquid Biopsy Product Offered
      • 11.6.3 Genomic Health Breast Cancer Liquid Biopsy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.6.4 Genomic Health Main Business Overview
      • 11.6.5 Genomic Health Latest Developments
    • 11.7 Thermo Fisher Scientific
      • 11.7.1 Thermo Fisher Scientific Company Information
      • 11.7.2 Thermo Fisher Scientific Breast Cancer Liquid Biopsy Product Offered
      • 11.7.3 Thermo Fisher Scientific Breast Cancer Liquid Biopsy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.7.4 Thermo Fisher Scientific Main Business Overview
      • 11.7.5 Thermo Fisher Scientific Latest Developments
    • 11.8 Illumina
      • 11.8.1 Illumina Company Information
      • 11.8.2 Illumina Breast Cancer Liquid Biopsy Product Offered
      • 11.8.3 Illumina Breast Cancer Liquid Biopsy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.8.4 Illumina Main Business Overview
      • 11.8.5 Illumina Latest Developments
    • 11.9 Biocept
      • 11.9.1 Biocept Company Information
      • 11.9.2 Biocept Breast Cancer Liquid Biopsy Product Offered
      • 11.9.3 Biocept Breast Cancer Liquid Biopsy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.9.4 Biocept Main Business Overview
      • 11.9.5 Biocept Latest Developments
    • 11.10 Trovagene
      • 11.10.1 Trovagene Company Information
      • 11.10.2 Trovagene Breast Cancer Liquid Biopsy Product Offered
      • 11.10.3 Trovagene Breast Cancer Liquid Biopsy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.10.4 Trovagene Main Business Overview
      • 11.10.5 Trovagene Latest Developments
    • 11.11 Guardant Health
      • 11.11.1 Guardant Health Company Information
      • 11.11.2 Guardant Health Breast Cancer Liquid Biopsy Product Offered
      • 11.11.3 Guardant Health Breast Cancer Liquid Biopsy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.11.4 Guardant Health Main Business Overview
      • 11.11.5 Guardant Health Latest Developments
    • 11.12 RainDance Technologies
      • 11.12.1 RainDance Technologies Company Information
      • 11.12.2 RainDance Technologies Breast Cancer Liquid Biopsy Product Offered
      • 11.12.3 RainDance Technologies Breast Cancer Liquid Biopsy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.12.4 RainDance Technologies Main Business Overview
      • 11.12.5 RainDance Technologies Latest Developments
    • 11.13 MDx Health
      • 11.13.1 MDx Health Company Information
      • 11.13.2 MDx Health Breast Cancer Liquid Biopsy Product Offered
      • 11.13.3 MDx Health Breast Cancer Liquid Biopsy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.13.4 MDx Health Main Business Overview
      • 11.13.5 MDx Health Latest Developments
  • 12 Research Findings and Conclusion

USD 3,660 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.